Seeking Alpha: AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...
AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma ...
Healio: FDA updates Airsupra prescribing information to include benefit in mild asthma
Please provide your email address to receive an email when new articles are posted on . The risk for severe exacerbations in mild asthma dropped with use of Airsupra vs. albuterol alone in the phase ...
Airsupra (albuterol/budesonide) is a prescription drug that’s used to manage asthma in adults. It also lowers the risk of an asthma attack. Airsupra comes as an aerosol that you inhale through your ...
Nasdaq: AstraZeneca : AIRSUPRA Gains FDA Label Update After Strong Results In Mild Asthma Patients
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) announced a major update to the U.S. prescribing information for AIRSUPRA, following new clinical evidence from the BATURA study. This Phase IIIb ...
AstraZeneca : AIRSUPRA Gains FDA Label Update After Strong Results In Mild Asthma Patients
Monthly Prescribing Reference: Airsupra Label Updated to Include Data on Use in Mild Asthma
With the inclusion of the BATURA study, Airsupra has now demonstrated its effectiveness in reducing the risk of severe exacerbations across all severity levels of asthma vs albuterol. The Food and ...